The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study.

Ann Transl Med · 2023 · PMC9951015 · PMID 36846007

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The median OS of the 2 groups showed a trend towards improved outcomes but without significant difference (13.3 vs. 7.6 months, P=0.098, Figure S2B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.